The tail vein is usually used, although other veins (e.g. penile vein,14 femoral vein15 and retro-orbital plexus16) have been used. A great deal of technical expertise is required to perform this, particularly in mice (due to the small size of their veins and their predisposition not to lie still despite restraint, particularly in the case of the C57BL/6 strain). The main complication of tail vein injection is skin necrosis in the event of tissue extravazation. Selleck LEE011 Due to the narrow therapeutic index of Adriamycin, a small difference
in dose administered can potentially lead to a large variation in disease severity. Another route of administration is the substernal intra-cardiac (∼7 mg/kg in male Wistar rats) approach,17 which requires general PFT�� anaesthesia. The intra-renal route, whereby Adriamycin is injected directly into the kidney (pre- and post-contralateral nephrectomy) is associated with induction of renal injury within 4 weeks. Direct injection
of the renal artery has not been used except in pharmacodynamic studies in dogs.18 Despite their reported safety, the invasiveness of the intra-cardiac and intra-renal routes of administration has precluded widespread application. Intraperitoneal administration has been favoured for its ease of use, particularly in mice19 but due to variable absorption through the peritoneal membrane, inconsistency in induction of renal injury compared with the intravenous route has made this method less favoured. A variety of conditions can affect the delivery of Adriamycin to the target organ. Temporary clipping of one renal artery during the intravenous administration of Adriamycin partially protects the clipped kidney from proteinuric renal injury.14,20 In addition, inhibition of renal blood flow by nitric
oxide inhibition protects against glomerulosclerosis. These studies provide substantial proof that Adriamycin acts directly on the kidney to induce tissue injury.21 Male rats are more Masitinib (AB1010) susceptible than female rats to Adriamycin-induced nephropathy. Castration renders male rats less susceptible compared with sham-operated rats, indicating that sex hormones may contribute to the pathogenesis of Adriamycin-induced renal injury.22 Because of the difference in severity of renal injury, choice of sex is a major factor in designing an experiment using AN as a model of renal injury. In this animal model, the histological changes resemble those of human focal glomerulosclerosis, with podocyte fusion, focal segmental and global glomerular sclerosis and tubulointerstitial inflammation and fibrosis (Fig. 1).23 Adriamycin induces thinning of the glomerular endothelium and podocyte effacement associated with loss of size- and charge-specific barrier to filtration of plasma proteins.11 These changes are seen as early as 1–2 weeks after Adriamycin injection, and are severe by 4 weeks (Fig. 2).